And lo, as the cannabis promoters try to ramp up interest in their sector again after a long dormancy, we are presented with yet another “secret” pot stock to sleuthify. The ad I’m looking at today is a teaser pitch from Don Yocham, Executive Director of the National Institute for Cannabis Investors (NICI), hosting an […]
Articles
Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions and his words and opinions are his own. You can see his biography and past articles here. In the beginning, there was a canopy, verdant and succulent, given to inky-black nights punctuated by the utterances […]
I’ve been puttering around and thinking about several different teaser ads recently, but this one percolated to the top of the pile when I read Alexander Green’s characterization of it as the “Easiest Grand-Slam Stock of the New Year” … so what is it? Well, the ad is for the basic membership in the Oxford […]
Cancer Care: Current Directions[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
For several years from 12-99 through about 4 years ago, Amylin Pharmaceuticals was 50% of my total portfolio. During my...
Back to the title article, from Forbes we get: Want to Fight a Deadly Fungus? San Diego's Amplyx Just Got $41M For That...